Research programme: sphingosine-1 phosphate receptor agonists - Almirall

Drug Profile

Research programme: sphingosine-1 phosphate receptor agonists - Almirall

Alternative Names: LAS 189913

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Almirall S.A.
  • Class
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 27 Jun 2014 No development reported - Preclinical for Multiple sclerosis in Europe (unspecified route)
  • 01 Feb 2012 Discontinued - Preclinical for Multiple sclerosis in Europe (unspecified route)
  • 26 Aug 2010 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Multiple sclerosis presented at the 240th American Chemical Society National Meeting (240th-ACS-2010) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top